Absorption, metabolism and elimination of N,N-dimethylformamide in humans
Jazyk angličtina Země Německo Médium print
Typ dokumentu časopisecké články
PubMed
1399028
DOI
10.1007/bf00381474
Knihovny.cz E-zdroje
- MeSH
- absorpce MeSH
- acetylcystein analogy a deriváty moč MeSH
- dimethylformamid analogy a deriváty metabolismus farmakokinetika MeSH
- dospělí MeSH
- formamidy metabolismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- plíce metabolismus fyziologie MeSH
- rozpouštědla metabolismus farmakokinetika MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- acetylcystein MeSH
- dimethylformamid MeSH
- formamidy MeSH
- N-acetyl-S-(N-methylcarbamoyl)cysteine MeSH Prohlížeč
- N-hydroxymethyl-N-methylformamide MeSH Prohlížeč
- N-hydroxymethylformamide MeSH Prohlížeč
- rozpouštědla MeSH
Excretion of N,N-dimethylformamide (DMF) and DMF metabolites N-hydroxymethyl-N-methylformamide ("MF"), N-hydroxymethyl-formamide ("F") and N-acetyl-S-(N-methylcarbamoyl)cysteine (AMCC) has been monitored in the urine of volunteers during and after their 8-h exposure to DMF vapour at a concentration of 10, 30 and 60 mg.m-3. The pulmonary ventilation in these experiments was typically about 10 l.min-1 and the retention in the respiratory tract was 90%. After exposure to 30mg DMF.m-3, the yield of compound determined in the urine represented 0.3% (DMF), 22.3% ("MF"), 13.2% ("F") and 13.4% (AMCC) of the dose absorbed via the respiratory tract. The excretion curves of the particular compounds attained their maximum 6-8h (DMF), 6-8h ("MF"), 8-14h ("F") and 24-34h (AMCC) after the start of the exposure. The half-times of excretion were approximately 2, 4, 7 and 23 h respectively. In contrast to slow elimination of AMCC after exposure to DMF, AMCC was eliminated rapidly after AMCC intake. This discrepancy could be explained by rate-limiting reversible protein binding of a reactive metabolic intermediate of DMF, possibly methylisocyanate.
Zobrazit více v PubMed
Life Sci. 1986 Feb 24;38(8):719-24 PubMed
Toxicol Appl Pharmacol. 1988 Aug;95(1):162-70 PubMed
J Occup Med. 1975 Aug;17(8):506-11 PubMed
J Occup Med. 1978 Mar;20(3):179-82 PubMed
Chem Biol Interact. 1983 Aug 1;45(3):387-92 PubMed
G Ital Med Lav. 1984 May-Jul;6(3-4):143-8 PubMed
J Chromatogr. 1988 Oct 14;431(2):361-8 PubMed
Toxicol Appl Pharmacol. 1989 May;98(3):507-16 PubMed
Chem Biol Interact. 1984 Aug;50(3):327-37 PubMed
Gig Tr Prof Zabol. 1978 Oct;(11):24-7 PubMed
Br J Ind Med. 1987 Dec;44(12):834-40 PubMed
Int Arch Occup Environ Health. 1980;46(2):159-65 PubMed
J Pharmacol Exp Ther. 1987 Jan;240(1):265-70 PubMed
Int Arch Occup Environ Health. 1980;45(3):189-203 PubMed
Int Arch Arbeitsmed. 1975;34(2):127-36 PubMed
Br J Ind Med. 1980 May;37(2):185-8 PubMed
Toxicology. 1981;22(1):1-7 PubMed
Scand J Work Environ Health. 1986 Dec;12(6):603-8 PubMed
Chem Res Toxicol. 1991 Jul-Aug;4(4):436-44 PubMed
Toxicology. 1984 Jan;29(3):221-34 PubMed
Int Arch Occup Environ Health. 1981;48(3):257-71 PubMed
Biochem J. 1953 Oct;55(3):416-21 PubMed
J Chromatogr. 1987 Mar 6;414(2):399-404 PubMed
Cancer Treat Rep. 1982 Nov;66(11):1957-65 PubMed
Toxicol Appl Pharmacol. 1972 Oct;23(2):271-6 PubMed
Arch Toxicol. 1984 Dec;56(2):87-91 PubMed
